Two-Year Treatment of Growth Hormone (GH) Receptor Deficiency with Recombinant Insulin-Like Growth Factor I in 22 Children: Comparison of Two Dosage Levels and to GH-Treated GH Deficiency1

Abstract excerpt

We have reported 1-yr results of a double blind, placebo-controlled trial of recombinant human insulin-like growth factor I (rhIGF-I) replacement in 16 children from the Ecuadorian GH receptor-deficient (GHRD) population. This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genetic Syndromes and Imprinting
• Share to Growth Hormone and Insulin-like Growth Factors
• Share to Lipid metabolism and disorders